MP3•Episode home
Manage episode 505889740 series 3689489
Content provided by KDIGO Communications. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by KDIGO Communications or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Why does it matter if a kidney disease is complement-driven or complement-associated?
Dr. Matthew Pickering (Imperial College London, United Kingdom) explains this critical distinction and why it changes how clinicians approach diagnosis and treatment. The discussion explores promising new therapies such as C3 and C5 inhibitors and how biomarkers are paving the way for precision medicine in nephrology.
This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).
This series was supported by Apellis and Sobi.
25 episodes